Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Photo/Multimedia, Product/Service

Prestige BioPharma Announces Grand Opening of Global-Scale Vaccine Center in South Korea


Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, is pleased to announce the grand opening of its global-scale Vaccine Center in Osong, South Korea.

The opening ceremony was held on December 01, 2021 at the Vaccine Center in Osong Campus. The ceremony was attended by many distinguished guests including Minister for Government Policy Coordination Mr. Yun-cheol Koo, Deputy Governor Mr. Il-hong Seong of Chungbuk Province, Mayor of Cheongju City Mr. Beom-deok Han, Representatives from Octava Fund Limited Mr. Joseph Tey and Mr. Sze Khai Pang.

PBP commenced construction of its Vaccine Center April this year and completed the global-scale manufacturing facility with a total area of 10,342.88 m2 and a total capacity of 104,000 litres (52 units of 2,000 liter bioreactors) in only eight months by employing Prestige Biologics (334970: KOSDAQ)' proprietary engineering technology, ALITA Smart BioFactoryTM. With the ALITA system which provides combined advantages of Stainless Steel & Single-Use system, different types of vaccines can be produced in versatile custom manufacturing suites. The Vaccine Center's Single-Use bioreactors also enhance operational efficiency and productivity while minimizing the risk of cross contamination.

PBP is currently focusing on two COVID19 vaccine projects to produce Sputink V and Sputink Light vaccines. PBP's global-scale Vaccine Center is capable of producing around 2.6 billion doses of the first dose of Sputnik V vaccine (Ad26 adenovirus vector) per year.

The center will soon be prepared to produce other types of vaccines including mRNA vaccines to actively respond to the growing demands of COVID19 vaccines.

The company ultimately aims to develop its own vaccine products to combat potential future pandemics and PBP Vaccine Center will be the basecamp for this journey.

PBP's CEO, Dr Lisa S. Park commented, "We are very pleased to complete the Prestige Biopharma Vaccine Center as planned this year with our Group's unique and unmatched engineering technology, ALITA Smart BioFactory" and "this Vaccine Center will be playing a significant role in our fight against Covid-19 and possible future pandemics".


These press releases may also interest you

at 05:05
BeiGene , a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China...

at 05:00
IT consulting and other services mainly include consulting, systems integration, and other services including information management and education and training, according to the latest research report of "IT Services Market in Nordic-Forecast and...

at 04:55
The "Body Fat Measurement Market Research Report by Product, by End User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Body Fat Measurement Market size...

at 04:40
The "Consumer Healthcare Market Research Report by Product, by Distribution, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Consumer Healthcare Market size...

at 04:32
Yum China Holdings, Inc. (the "Company" or "Yum China", NYSE: YUMC and HKEX: 9987) announced that the Top Employers Institute has certified the Company as a Top Employer China for the fourth consecutive year, with Yum China the only restaurant...

at 04:30
The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the...



News published on 30 november 2021 at 23:10 and distributed by: